Drug Trial Radar · NCT07483450
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 4, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).
Conditions
- Relapsing Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
Interventions
OcrelizumabDrug
Ocrelizumab will be administered as per the schedule specified in the respective arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- RMS Cohort: Annualized Protocol-defined Relapse RateTime frame: Up to approximately 1.6 years
- PPMS Cohort: B-cell Levels in BloodTime frame: Up to Week 48
- PPMS Cohort: Percentage of Participants Achieving Cluster of Differentiation 19 (CD19+) B-cell Levels of <10 Cells/Microliter (μL) at Week 48Time frame: At Week 48
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China
Peking University First Hospital
Beijing, China
Beijing Hospital of Ministry of Health
Beijing, China
Xiangya Hospital Central South University
Changsha, China
West China Hospital of Sichuan University
Chengdu, China
The First Affiliated Hospital, Chongqing Medical University
Chongqing, China
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
The Third Affiliated Hospital of Sun Yat-Sen University
Guangzhou, China
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, China
Inner Mongolia Autonomous Region People's Hospital
Hohhot, China
Lanzhou University Second Hospital
Lanzhou, China
The First Hospital of China Medical University
Shenyang, China
The Second Hospital of Hebei Medical University
Shijiazhuang, China
1st Affiliated Hospital of Shanxi Medical University
Taiyuan, China
Xinjiang People Hospital
Ürümqi, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.